Humacyte, Inc. (HUMA)

NMS – Цена в реальном времени. Валюта: USD

0.91

-0.09 (-9.00%)

При закрытии: May 12, 2026, 4:00 PM EDT

0.95

+0.04 (4.40%)

До открытия: May 13, 2026, 4:46 AM EDT

08.05.2026

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte, Inc. (HUMA) closed at $1.06 in the latest trading session, marking a -1.85% move from the prior day.

08.05.2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”).On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engi.

08.05.2026

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

28.04.2026

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

27.04.2026

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, April 28, 2026 at 8:00 AM ET featuring Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center, Salisbury VA Medical Center), and Mohamad A.

25.04.2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

24.04.2026

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.7, indicating a -1.14% shift from the previous trading day.

Видео

No Data

There is no data to display

Пресс-релизы

08.05.2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

27.04.2026

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

25.04.2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

24.04.2026

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S. distribution of Symvess remain unchanged DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius Medical Care (FME).

Humacyte, Inc. (HUMA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Humacyte, Inc. (HUMA)

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Видео

No Data

Пресс-релизы

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Видео

No Data

Пресс-релизы

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Search stocks

Humacyte, Inc. (HUMA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Humacyte, Inc. (HUMA)

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Видео

No Data

Пресс-релизы

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Видео

No Data

Пресс-релизы

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®